title: [Prophylaxis of deep vein thrombosis with enoxaparin 40 mg in outpatients compared to hospitalized medically ill patients].
abstract: OBJECTIVE
  The efficacy and safety of enoxaparin 40 mg in the prevention of thromboembolic events have been examined in immobilized nonsurgical hospitalized patients as well as in the outpatient setting.
  
  
  METHODS
  800 outpatients from 275 sites and 381 patients from 80 hospitals with an acute medical illness leading to a reduced physical activity were enrolled in a national, multicenter, noninterventional, observational study. The primary endpoint included all clinical signs of a deep vein thrombosis (DVT) and/or pulmonary embolism during the prophylaxis and up to 48 h after discontinuation. The patients were treated 9-14 days on average.
  
  
  RESULTS
  There were few differences between the inpatients and the outpatients with respect to reduced mobility. However, the proportion of patients with infectious diseases was much higher in outpatients (53.8%) than in hospitalized patients (37.5%). The incidences of diseases of the musculoskeletal system (outpatients 20.9% vs. inpatients 7.3%) and acute congestive heart failure (outpatients 16.5% vs. inpatients 25.1%) were not balanced. During the observational period, primary endpoints were detected as clinical signs of a DVT in two outpatients aged > 65 years (0.3%) and were confirmed by ultrasound. Major bleedings were reported as secondary endpoints in only two hospitalized patients.
  
  
  CONCLUSIONS
  The results of this noninterventional study show that a primary prophylaxis with enoxaparin 40 mg in nonsurgical outpatients shows a similar safety profile compared to hospitalized medically ill patients.
authors.affiliation: Klinik für Angiologie, HELIOS-Klinikum Krefeld, Krefeld, Germany. knut.kroeger@helios-kliniken.de
authors.forename: Knut
authors.initials: K
authors.lastname: Kröger
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000553:Ambulatory Care; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D017984:Enoxaparin / Q000627:therapeutic use*; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced / Q000453:epidemiology; D006760:Hospitalization; D006801:Humans; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D051346:Mobility Limitation; D011655:Pulmonary Embolism / Q000453:epidemiology / Q000517:prevention & control; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000453:epidemiology / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D017984:Enoxaparin
references.citation: J Thromb Thrombolysis. 2006 Aug;22(1):31-8
references.pmid: 16786230
references.citation: BMJ. 2006 Feb 11;332(7537):325-9
references.pmid: 16439370
references.citation: N Engl J Med. 1999 Sep 9;341(11):793-800
references.pmid: 10477777
references.citation: Lancet. 2006 Apr 1;367(9516):1075-1079
references.pmid: 16581406
references.citation: Circulation. 2004 Aug 17;110(7):874-9
references.pmid: 15289368
references.citation: Int Angiol. 2006 Jun;25(2):101-61
references.pmid: 16763532
references.citation: J Thromb Haemost. 2005 Jul;3(7):1459-66
references.pmid: 15978103
references.citation: Chest. 2008 Jun;133(6 Suppl):381S-453S
references.pmid: 18574271
references.citation: Clin Appl Thromb Hemost. 2007 Jan;13(1):7-13
references.pmid: 17164492